Journal of Hepatology最新文献

{"title":"Response to: Sequential therapy with antisense oligonucleotide and immune modulator as a strategy for HBV cure","authors":"Maria Buti, Jeong Heo, Maximilian Lee","doi":"10.1016/j.jhep.2024.12.012","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.12.012","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Financial support</h2>GSK study 209348</section></section><section><section><h2>Authors’ contributions</h2>The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors, take responsibility for the integrity of the work as a whole, contributed to the writing and reviewing of the article, and have given final approval for the version to be published. Maria Buti and Jeong Heo contributed to the acquisition of data and data interpretation. Maximilian Lee contributed to the conception and design of the study, and the data analysis and interpretation.</section></section><section><section><h2>Declaration of Competing Interest</h2>MB has received grant support from Gilead and AbbVie, consultant fees from Gilead, AbbVie, Roche, Altimmune, and GSK, and lecture fees from Altimmune. JH has received grant support from Gilead and Roche, has received consultant fees from Roche, and lecture fees from AbbVie Korea, Roche, Yuhan Korea, Oncolys and Gilead, and is a member of an AstraZeneca steering committee. ML is an employee of and holds financial equities in GSK.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"20 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142797602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sedoanalgesia During TIPS Placement: Balancing Comfort and Safety in Diverse Clinical Settings","authors":"Yong Lv, Zhengyu Wang, Bohan Luo, Guohong Han","doi":"10.1016/j.jhep.2024.12.013","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.12.013","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>Yong Lv, Zhengyu Wang, Bohan Luo and Guohong Han designed the letter; Yong Lv drafted the letter; Guohong Han revised the letter.</section></section><section><section><h2>Financial support</h2>None.</section></section><section><section><h2>Declaration of Competing Interest</h2>All authors have nothing to declare.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section><section><section><h2>Acknowledgements</h2>None.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"97 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142797518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A read-through circular RNA RCRIN inhibits metabolic dysfunction-associated steatotic liver disease","authors":"Yanying Wang, Jianyi Wang, Ziheng Zhou, , Xiaoxiao Zhu, Zhibin Yi, Changchang Cao, Lei He, Ying Du, Hui Guo, Yong Tian, Zusen Fan","doi":"10.1016/j.jhep.2024.11.052","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.052","url":null,"abstract":"<h3>Background &amp; Aims</h3>The molecular mechanism underlying metabolic dysfunction-associated steatotic liver disease (MASLD) is elusive and whether non-coding RNAs can serve as biomarkers and therapeutic targets of MASLD is less defined.<h3>Methods</h3>Exon capture RNA sequencing analysis was used to identify read-through circRNAs (rt-circRNAs) in livers from three MASLD patients and three patients without MASLD. Hepatocyte-specific deletion or overexpression of rt-circRNA <em>RCRIN</em> were utilized to study MASLD pathogenesis.<h3>Results</h3>We identified 1126 rt-circRNAs in the liver tissues from MASLD patients. <em>RCRIN</em> was highly expressed in normal livers and was downregulated in MASLD livers. <em>Rcrin</em> deletion in hepatocytes caused lipid accumulation and MASLD development, while <em>Rcrin</em> overexpression suppressed the MASLD progression. Mechanistically, in normal hepatocytes, highly expressed <em>RCRIN</em> bound to RPL8 protein to recruit RNF2 for its degradation, reducing RPL8-contained ribosome numbers and lipid accumulation. In MASLD livers, lowerly expressed <em>RCRIN</em> released RPL8 protein to promote RPL8-contained ribosome numbers and lipid synthesis, leading to higher lipid accumulation and ER stress. We synthesized <em>RCRIN</em> and N-acetylgalactosamine (GalNAc)–Rpl8 siRNA to treat established MASLD in mice, both of which suppressed MASLD pathogenesis.<h3>Conclusions</h3>Our findings provide an <em>in vivo</em> function of rt-circRNA <em>RCRIN</em>, show its inhibitory effects in MASLD pathogenesis, indicating <em>RCRIN</em> and RPL8 may be therapeutic targets and candidate nucleic acid drugs for treating MASLD.<h3>Impact and Implications</h3>Our finds reveal a novel mechanism connecting a read-through circRNA <em>RCRIN</em>, ribosome heterogeneity and MASLD pathogenesis. In normal hepatocytes, <em>RCRIN</em> exerts its role by reducing liver lipid accumulation and ER stress through promotion of RPL8 degradation. In MASLD patients, lower <em>RCRIN</em> releases RPL8 to form RPL8-contained ribosomes to promote lipid accumulation and ER stress. <em>RCRIN</em> overexpression and RPL8 depletion dramatically suppresses MASLD development and progression. Our findings indicate that <em>RCRIN</em> and RPL8 might be potential therapeutic targets for treatment of MASLD patients.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"22 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142797383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta","authors":"Elisabetta Degasperi, Caroline Scholtes, Barbara Testoni, Sara Uceda Renteria, Maria Paola Anolli, Caroline Charre, Floriana Facchetti, Marie-Laure Plissonnier, Dana Sambarino, Riccardo Perbellini, Sara Monico, Annapaola Callegaro, Ester García-Pras, Sabela Lens, Maria Francesca Cortese, Xavier Forns, Sofía Pérez-del-Pulgar, Marintha Heil, Massimo Levrero, Fabien Zoulim, Pietro Lampertico","doi":"10.1016/j.jhep.2024.11.051","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.051","url":null,"abstract":"<h3>Background and aim</h3>Serum HBV RNA and HBcrAg levels have been proposed as useful biomarkers in the management of HBV patients, however their role in chronic hepatitis Delta (CHD) is currently unknown.<h3>Methods</h3>Consecutive untreated CHD patients were enrolled in a cross-sectional study in three EU centers. Clinical and virological characteristics were collected. Serum HBV RNA and HBcrAg levels were quantified by an automated real-time investigational assay (Cobas® 6800, Roche Diagnostics, Pleasanton, Ca, USA) and by LUMIPULSE® G HBcrAg assay (Fujirebio Europe), respectively. In 18 patients with available liver biopsies, intrahepatic analyses were performed.<h3>Results</h3>Overall, 240 HDV patients were enrolled: median age 46 years, 62% males, 53% cirrhotics, 57% NUC-treated, median ALT 70 U/L, HBsAg 3.8 log₁₀ IU/mL, 88% HBeAg-negative, median HDV RNA 4.9 log₁₀ IU/mL. HBV RNA tested positive (&gt;10 cp/mL) in only 8% of the patients [median 40 (13-82,000) cp/mL], whereas HBcrAg was ≥3 log₁₀ U/mL in 77% [median 4.2 (3.0-8.0) log₁₀ U/mL]. By combining these biomarkers, 3 categories were identified: 23% double negative (HBV RNA neg/HBcrAg neg), 9% double positive (HBV RNA pos/HBcrAg pos) and 68% HBV RNA negative/HBcrAg positive. HBV RNA levels positively correlated with male sex and detectable HBV DNA, while positive HBcrAg correlated with higher HBsAg levels. Double positive patients were younger, non-European, with elevated ALT and HDV RNA levels and detectable HBV DNA. Intrahepatic HDV RNA and HBV RNA were positive in most samples, while intrahepatic levels of covalently closed circular (ccc)DNA were low.<h3>Conclusions</h3>In untreated CHD, most patients had undetectable HBV RNA but quantifiable HBcrAg (“divergent pattern”) in the absence of HBeAg. Additional studies aimed to unravel the molecular mechanisms underlying these findings are warranted.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"36 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142797527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adolescent sobriety under siege – an urgent call to protect children from alcohol harms","authors":"Victoria T. Kronsten, Frank E. Murray, Shira Zelber-Sagi, Aleksander Krag, Debbie L. Shawcross","doi":"10.1016/j.jhep.2024.12.010","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.12.010","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Conflict of interest statement:</h2>VTK and FEM have no conflicts to disclose. SZS received a one-time consultant for Siemens and a one-time talk supported by AbbVie. AK has served as speaker for Novo Nordisk, Norgine and Siemens and participated in advisory boards for Siemens, Boehringer Ingelheim and Novo Nordisk, all outside the submitted work. Research support; Astra, Siemens, Nordic Bioscience, Echosense. Board member and co-founder Evido. DLS has undertaken consultancy for Norgine Pharmaceuticals Ltd, EnteroBiotix, MRM</section></section><section><section><h2>Specific author contributions:</h2>VTK wrote the first draft of this manuscript. FEM, SZS, AK and DLS reviewed and revised the manuscript. All authors approved the final submitted manuscript.Protecting children against alcohol consumption is failing. The World Health Organization (WHO) report (2024) on adolescent substance use in Europe, Central Asia and Canada¹ serves as a compelling call to action to strengthen alcohol harm prevention strategies targeting the young.Substance use in adolescents is a major public health concern,</section></section><section><section><h2>Funding:</h2>No funding was received for the preparation of this manuscript.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"5 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142797517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Clinical Utility of CT DNA Monitoring for Recurrence Prediction in Resected Extrahepatic Cholangiocarcinoma","authors":"Ying Zhang, Kui Wang, Zhengji Song","doi":"10.1016/j.jhep.2024.11.040","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.040","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Author’s contributions</h2>Kui Wang ,Ying Zhang: Study design &amp; Manuscript Writing.Zhengji Song: Study design &amp; Manuscript Revision.</section></section><section><section><h2>Data availability</h2>Not applicable</section></section><section><section><h2>Declaration of Competing Interest</h2>We declare there is no any conflict of interest.</section></section><section><section><h2>Acknowledgements &amp; Funding</h2>This work was supported by the National Natural Science Foundation of China (No.82360120), and the Yunnan Province Famous Doctor program (KH-SWR-MY-2019-009).</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"28 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142797519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fecal Microbiota Transplantation in a Long-Standing Auto-Brewery Syndrome with Complex Symptomatology","authors":"Marta Casañas-Martínez, Raquel Barbero-Herranz, Diana Alegre-González, José D. Mosquera-Lozano, Rosa del Campo","doi":"10.1016/j.jhep.2024.12.005","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.12.005","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Ethical Committee</h2>The research was conducted ethically, in accordance with the World Medical Association Declaration of Helsinki. The patient signed a written informed consent form.</section></section><section><section><h2>Authors' contributions</h2>M. Casañas-Martínez, D. Alegre-González and J.D. Mosquera-Lozano are the medical staff who treated the patient. R. Barbero-Herranz is the bioinformatics researcher who analysed the sequencing data, and R. del Campo is responsible for the Faecal Microbiota Transplantation programme and fundraising.</section></section><section><section><h2>Data availability statement</h2>The genomic sequences are available on the BioProject ID: PRJNA1188549.</section></section><section><section><h2>Declaration of Competing Interest</h2>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</section></section><section><section><h2>Acknowledgments And Fundings</h2>This research was also supported by Personalized and precision medicine grant from the Instituto de Salud Carlos III (MePRAM Project, PMP22/00092), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación. Funded by NextGenerationEU funds from the European Union that finance the actions of the The Resilience and Recovery Facility.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"199 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: main changes and potential implications for the next major liver society clinical practice guidelines","authors":"Grace Lai-Hung Wong, Maud Lemoine","doi":"10.1016/j.jhep.2024.12.004","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.12.004","url":null,"abstract":"Progress towards hepatitis B virus (HBV) global elimination has been slow and most countries are far to reach the elimination targets set up by the World Health Organization (WHO). The burden of chronic hepatitis B is mainly bear by resource-limited countries where only a minority of people living with HBV are diagnosed and treated and international guidelines hardly applicable in real-life. In March 2024, the WHO released its revised guidelines for the prevention and management of chronic hepatitis B. Simplification of care and expansion of treatment criteria represent the core of this revision. Whether and how these updated WHO guidelines will influence the international liver societies (EASL, AASLD and APASL) for their next hepatitis B recommendations remain uncertain. Yet, the European, American and Asian regions encompass multiple low, middle and intermediate-income countries with high HBV endemicity and vulnerable populations that should benefit from simplified clinical algorithms. Here, from an analysis of the WHO guideline development process and its new recommendations, we aimed to identify the anticipated areas of agreements and controversies with the next liver society hepatitis B guidelines which will have to balance clinical risks and benefits for the patients.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"40 5 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Control compounds for drug-induced liver injury evaluation: Evidence from Database of Adverse Event Notifications","authors":"Guiying Gao, Guo Yu, Guo-Fu Li","doi":"10.1016/j.jhep.2024.12.002","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.12.002","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors’ contributions:</h2>Guo-Fu Li concepted and designed the study, analyzed and interpreted the data, and drafted the manuscript; Guiying Gao and Guo Yu contributed to the data collection and analysis; Guo Yu and Guo-Fu Li supervised the study. All authors reviewed and approved the final manuscript.</section></section><section><section><h2>Data availability statement:</h2>The data used in this study can be publicly accessible at <span><span>https://www.tga.gov.au/safety/safety/database-adverse-event-notifications-daen-medicines</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> in the Database of Adverse Event Notifications.</section></section><section><section><h2>Financial support:</h2>Guo Yu reports receiving grants from Jiangsu Provincial Natural Science Fund for Distinguished Young Scholars (BK20200005).</section></section><section><section><h2>Declaration of Competing Interest:</h2>The authors declare no conflicts of interest that pertain to this work.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"7 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142763313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reflections on HBV Adaptation and Immune Interactions: Insights and Future Directions","authors":"Ziyi He, Chenxi Wang, Huichuan Tian","doi":"10.1016/j.jhep.2024.11.046","DOIUrl":"https://doi.org/10.1016/j.jhep.2024.11.046","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Declaration of Competing Interest</h2>The authors declare no conflicts of interest that pertain to this work.</section></section><section><section><h2>Financial support statement</h2>No fundings were received for this research.</section></section><section><section><h2>Data availability</h2>No datasets were generated or analysed during the current study.</section></section><section><section><h2>Authors contributions</h2>CX W, ZY H: Methodology, Formal analysis, Writing - Original Draft; HC T: Conceptualization, Methodology, Supervision, Writing - Review &amp; Editing.</section></section><section><section><h2>Funding</h2>No funding was received to assist with the preparation of this manuscript.</section></section><section><section><h2>Declaration of Competing Interest</h2>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"261 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142763306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}